

ADURO BIOTECH, INC.  
Form SC 13G  
February 12, 2016

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(b)  
(Amendment No. )1

Aduro Biotech, Inc.  
(Name of Issuer)

Common Stock, \$.0001 par value  
(Title of Class of Securities)

00739L101  
(CUSIP Number)

December 31, 2015  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

---

1 The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.



CUSIP No. 00739L101

1. NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
  
Johnson & Johnson  
EIN: 22-1024240
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A (a) [ ]  
GROUP (b) [ ]
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION  
New Jersey
- |              |    |                                     |
|--------------|----|-------------------------------------|
| NUMBER OF    | 5. | SOLE VOTING POWER -0-               |
| SHARES       | 6. | SHARED VOTING POWER 3,906,207*      |
| BENEFICIALLY | 7. | SOLE DISPOSITIVE POWER -0-          |
| OWNED BY     | 8. | SHARED DISPOSITIVE POWER 3,906,207* |
| EACH         |    |                                     |
| REPORTING    |    |                                     |
| PERSON       |    |                                     |
| WITH         |    |                                     |
9. AGGREGATE AMOUNT BENEFICIALLY OWNED  
BY EACH REPORTING PERSON 3,906,207\*
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)  
EXCLUDES CERTAIN SHARES [ ]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.2%\*\*
12. TYPE OF REPORTING PERSON CO

\* As of December 31, 2015

\*\* Based on 63,224,033 shares of Common Stock outstanding as of November 20, 2015, as reported in the Issuer's Report on Form 10-Q for the period ended September 30, 2015 filed with the Securities and Exchange Commission on November 23, 2015.

---

CUSIP No. 00739L101

1. NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Johnson & Johnson Innovation-JJDC, Inc.  
EIN: 22-2007137

2. CHECK THE APPROPRIATE BOX IF A MEMBER (a)   
OF A GROUP (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION  
New Jersey

NUMBER OF	5.	SOLE VOTING POWER -0-
SHARES	6.	SHARED VOTING POWER 3,906,207*
BENEFICIALLY	7.	SOLE DISPOSITIVE POWER -0-
OWNED BY	8.	SHARED DISPOSITIVE POWER 3,906,207*
EACH		
REPORTING		
PERSON		
WITH		

9. AGGREGATE AMOUNT BENEFICIALLY OWNED  
BY EACH REPORTING PERSON 3,906,207\*

10. CHECK BOX IF THE AGGREGATE AMOUNT IN  
ROW (9) EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.2%\*\*

12. TYPE OF REPORTING PERSON CO

\* As of December 31, 2015

\*\* Based on 63,224,033 shares of Common Stock outstanding as of November 20, 2015, as reported in the Issuer's Report on Form 10-Q for the period ended September 30, 2015 filed with the Securities and Exchange Commission on November 23, 2015.

CUSIP No. 00739L101

SCHEDULE 13G

ITEM NAME OF ISSUER:

1(a)

Aduro Biotech, Inc.

ITEM ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

1(b)

626 Bancroft Way, 3C  
Berkeley, CA 94710

ITEM NAME OF PERSON FILING:

2(a)

This statement is being filed by Johnson & Johnson, a New Jersey corporation ("J&J"), and Johnson & Johnson Innovation-JJDC, Inc., a New Jersey corporation ("JJDC"). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC. J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC.

ITEM ADDRESS OF PRINCIPAL BUSINESS OFFICE:

2(b)

One Johnson & Johnson Plaza  
New Brunswick, NJ 08933

ITEM CITIZENSHIP:

2(c)

J&J: New Jersey  
JJDC: New Jersey

ITEM TITLE OF CLASS OF SECURITIES:

2(d)

Common Stock, \$.0001 par value per share ("Common Stock")

ITEM CUSIP NUMBER:

2(e)

00739L101

STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C):

ITEM

3

Not applicable.

ITEM OWNERSHIP:

4

The information set forth in Rows 5 through 9 and 11 of the cover pages of this Schedule 13G is incorporated herein by reference.

ITEM OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

5

Not applicable.

ITEM OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

6

Not applicable.

ITEM IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY:

7

Not applicable.

CUSIP No. 00739L101

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: February 3, 2016

JOHNSON & JOHNSON

By: /s/ Thomas Spellman III  
Name: Thomas Spellman III  
Title: Secretary

JOHNSON & JOHNSON  
INNOVATION-JJDC, INC.

By: /s/ Steven M.  
Rosenberg  
Name: Steven M. Rosenberg  
Title: Secretary